| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Neurosurgical Laboratories, Brigham and Women's Hospital [R. S. C., D. G., K. D., P. M. B.]; Brain Tumor Center, Brigham and Women's Hospital [R. S. C., D. G., K. D., P. M. B.]; The Children's Hospital [R. S. C., D. G., K. D., P. M. B.]; and Dana Farber Cancer Institute [P. N. B.], Department of Surgery, Harvard Medical School [R. S. C., D. G., K. D., P. M. B.], Boston, Massachusetts 02115
The possibility that the female sex steroid progesterone plays a role in meningioma proliferation has been suggested by a number of investigators; and it had been shown that many meningiomas have high affinity progesterone binding sites. The aim of this study was to examine the expression of progesterone receptor mRNA and correlate it with the nuclear localization of progesterone receptor by immunocytochemistry in a large number of meningiomas. Thirty-three meningiomas were examined for the presence of measurable amounts of progesterone receptor mRNA by Northern blot analysis and 11 of these were analyzed for receptor protein by immunohistochemistry. These were compared with normal arachnoid and an arachnoid cell line.
Sixty-four % of the meningiomas expressed progesterone receptor mRNA. This occurred in a similar pattern to what has previously been shown for T-47 D cells, a breast carcinoma cell line with 11.4-, 6.1-, 5.2-, 4.5-, 3.2-, and 2.5-kilobase mRNA species. This suggests that progesterone receptor expression is not tumor specific. There was a marked predominance of women among those patients whose tumors expressed progesterone receptor; 81% were female and 19% were male. The immunohistochemistry data correlate well with the Northern blot analysis. The staining was clearly nuclear, suggesting that the receptor is in a location to be activated.
These data suggest that progesterone receptor mRNA and protein is expressed in meningiomas and support the concept that progesterone may play an important role in meningioma growth.
1 To whom requests for reprints should be addressed.
Received 9/25/92. Accepted 1/ 6/93.
This article has been cited by other articles:
|
|
 |
|
  M. D. Tabernero, A. B. Espinosa, A. Maillo, O. Rebelo, J. F. Vera, J. M. Sayagues, M. Merino, P. Diaz, P. Sousa, and A. Orfao Patient Gender Is Associated with Distinct Patterns of Chromosomal Abnormalities and Sex Chromosome Linked Gene-Expression Profiles in Meningiomas Oncologist, October 1, 2007; 12(10): 1225 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O.D. Slayden, M.B. Zelinski, K. Chwalisz, H. Hess-Stumpp, and R.M. Brenner Chronic progesterone antagonist-estradiol therapy suppresses breakthrough bleeding and endometrial proliferation in a menopausal macaque model Hum. Reprod., December 1, 2006; 21(12): 3081 - 3090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Roser, M Nakamura, M Bellinzona, S K Rosahl, H Ostertag, and M Samii The prognostic value of progesterone receptor status in meningiomas J. Clin. Pathol., October 1, 2004; 57(10): 1033 - 1037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Moss, R. DeCastro, N. J. Patronas, and A. Taveira-DaSilva Meningiomas in Lymphangioleiomyomatosis JAMA, October 17, 2001; 286(15): 1879 - 1881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kubo, T. Fukutomi, S. Akashi-Tanaka, and T. Hasegawa Association of Breast Cancer with Meningioma: Report of a Case and Review of the Literature Jpn. J. Clin. Oncol., October 1, 2001; 31(10): 510 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Carroll, M. Brown, J. Zhang, J. DiRenzo, J. Font De Mora, and P. McL. Black Expression of a Subset of Steroid Receptor Cofactors Is Associated with Progesterone Receptor Expression in Meningiomas Clin. Cancer Res., September 1, 2000; 6(9): 3570 - 3575. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. L. Wagner, G. Pollio, P. Giangrande, J. C. Webster, M. Breslin, D. E. Mais, C. E. Cook, W. V. Vedeckis, J. A. Cidlowski, and D. P. McDonnell The Novel Progesterone Receptor Antagonists RTI 3021-012 and RTI 3021-022 Exhibit Complex Glucocorticoid Receptor Antagonist Activities: Implications for the Development of Dissociated Antiprogestins Endocrinology, March 1, 1999; 140(3): 1449 - 1458. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Perrot-Applanat, K. Cohen-Solal, E. Milgrom, and M. Finet Progesterone Receptor Expression in Human Saphenous Veins Circulation, November 15, 1995; 92(10): 2975 - 2983. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
